Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...

Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab ...

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company"), a global biopharmaceutical company, and mAbxience ("mAbxience") today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Teens often spend hours daily watching videos online, but parents should consider how the content affects their well-being ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...

Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug ...

In this article, we explore how aging impacts the musculoskeletal system and share expert-backed prevention tips to help you ...

Osteoporosis, often called a silent disease, weakens bones and increases the risk of fractures, making it a leading cause of ...

Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market. Amgen sells ...

In a Korean national study, osteoporotic fracture was associated with higher risks for graft failure and death among kidney transplant recipients. Bone fracture from osteoporosis in kidney transplant ...